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Coronavirus disease 2019 (COVID-19) is associated with marked albeit variable hemostasis 
disturbances and high thrombotic risk (1). Measurement of plasma D-dimers levels has been put 
forward as a prognostic marker (2). However, more comprehensive functional tests, such as 
thrombin generation and fibrinolysis assay, could also be of clinical relevance to estimate risks 










studies only describe the longitudinal follow-up of hemostasis parameters - a worrying gap in the 
close assessment of the course of the hemostasis disturbances during the acute phase of the 
disease. 
The aim of this prospective study was therefore to describe the longitudinal changes in 
hemostasis parameters assessed daily in 21 COVID-19 patients during their intensive care unit 
(ICU) stay. Our main findings were that (i) daily standard measurements consistent with a 
prothrombotic state persisted over the first days and improved thereafter, but did not normalize 
in all patients; (ii) increased thrombin potential (hypercoagulability) and decreased fibrinolysis 
were frequent and (iii) a high inter-patient variability was observed. 
 
The study was conducted at the CHU UCL Namur (Godinne site, Belgium) after approval 
from the local Ethics Committee (NUB: B0392020000031). All adult patients managed at the 
ICU for an RT-PCR-confirmed SARS-CoV-2 infection from March 27 to April 24, 2020 were 
considered for inclusion. One patient was not included due to refusal of advanced respiratory 
support or resuscitation.  
Patients were managed according to the internal standard of care. Guidance from the French 
Interest Group in Perioperative Hemostasis (GIHP) was implemented for anticoagulation 
management on April 2, 2020 (3).  
Blood was collected once a day at approximately 4 a.m. CRP levels were measured on a  
Vitros 5600 Integrated System (Ortho Clinical Diagnostics, Belgium) with CRP gold latex 
reagent (DiAgam, Ghislenghien, Belgium) and platelet count by impedance method on a Sysmex 
XN-20 analyser with Cellpack reagent (Sysmex Corporation, Kobe, Japan). Hemostasis tests 










Vacuette, Greiner Bio One, Kremsmünster, Austria) blood centrifuged (1,500 g 15 minutes) 
within 1 hour after collection. Remaining plasma underwent a second centrifugation (same 
conditions) and was stored at -80°C within 4 hours after the first centrifugation. Additional tests 
were performed using frozen-thawed (37°C; 5 minutes) plasma samples. The following 
laboratory parameters were measured with a STA-R Max analyzer: prothrombin time (PT; STA-
NeoPTimal, Diagnostica Stago, Asnières-sur-Seine, France), heparin anti-Xa activity (STA-
Liquid anti-Xa, Stago), Clauss fibrinogen (STA-Liquid FIB, Stago), clotting factor VIII (STA-
C.K. Prest and STA – Immunodef VIII, Stago), D-dimers (STA–LIATEST D-Di Plus, Stago), 
antithrombin (STA-Stachrom, Stago), and PAI-1 levels (Stachrom PAI-1, Stago). Thrombin 
generation was studied with the ST Genesia analyzer using the STG-ThromboScreen reagent 
(Stago). Heparin was fully neutralized with a hexadimethrine bromide solution (final 
concentration in the test: 25µg/mL; polybrene, Sigma Aldrich, Saint-Louis, United States) before 
thrombin generation measurement. The endogenous thrombin potential (ETP) was normalized 
against a reference plasma provided with the STG-ThromboScreen kit (Stago). Fibrinolysis was 
investigated using the global fibrinolytic capacity test (Hyphen Biomed, Neuville-sur-Oise, 
France), a turbidity-based monitoring of clot dissolution accelerated by exogenous tPA. This test 
was performed with the Lysis Timer instrument (SD Innovation, Frouard, France): the clot lysis 
time (in minutes) corresponds to the point where the lysis velocity is the fastest; the longer the 
lysis time, the lower the fibrinolysis capacity (4). 
 
Clinical characteristics of the 21 study patients are presented in Figure 1. Median monitoring 
duration was 15 days (IQR: 7-26, min-max range: 4-28). Median age was 60 (IQR: 57-64, min-










32, min-max range: 21-42). Median SOFA score at admission was 6 (IQR: 4-8, min-max range: 
2-12). The patient who fulfilled ISTH criteria for overt DIC died, as two other did after 
confirmed thrombotic complications, which were considered as main contributors of death. 
Twelve patients presented at least one bleeding event during the study period (major according to 
the ISTH in six; no deaths). 
Changes in hemostasis parameters and C-reactive protein (CRP) monitored daily during ICU 
stay are represented in Figure 2; in total there were 354 patients-days. Patients initially were in a 
high inflammatory state (median CRP levels of 204 mg/dL during the first ten days after ICU 
admission); CRP levels progressively decreased over time thereafter. Daily platelet counts were 
often normal and never below 70x10
9
/L. Prothrombin time was only moderately (+3 to +6 
seconds) and transiently increased in four patients, and markedly increased (+6 seconds) in the 
patient who fulfilled overt DIC criteria. Fibrinogen levels were markedly and persistently high 
(median value over the ICU stay: 665 mg/dL). The same held true for factor VIII levels (median 
value over the ICU stay: 304 %).  
The median value of D-dimers levels was 3’440 ng/mL, reaching very high levels in 
seven patients, above the upper limit of measurement (20,000 ng/mL), and tended to decrease 
over time. These findings are in line with previous reports (2). In addition they show that the 
increase in D-Dimers levels is a sustained process despite heparin administration (even with 
intensified prophylactic regimens), clinical improvement and decrease in CRP levels.  
Antithrombin deficiency (<80%) was detected in 13 patients, severe (<50%) in three, 
contributing to hypercoagulability. There was very little evidence for a consumptive process 
though since platelet counts were preserved, clotting times were only slightly prolonged, and 










One of the best approaches to evidence hypercoagulability in vitro is thrombin generation, 
which is now more accessible in the clinical environment thank to automated analyzers. 
Neutralization of heparin permitted the use of reagents more sensitive to coagulation 
abnormalities (i.e. STG-ThromboScreen) (5). At variance with previous reports we observed 
increased thrombin potential (5-7), median ETP values being above the published reference 
range (8) over the first week after ICU admission. Further work is required to understand the 
discrepant reports.   
PAI-1 plasma levels were increased at some time-points at least since the start of the 
observation period of all patients, fitting with the reduced global fibrinolytic capacity we 
observed. Published data so far are consistent with defective fibrinolysis in COVID-19 patients 
(which is not unique to this infectious condition), using viscoelastometric assays modified with 
tPA addition (5, 6, 9). It is intriguing that D-dimers plasma levels can be so high with defective 
fibrinolysis. As already hypothesized, this could be due to extravascular (e.g. pulmonary alveoli) 
fibrin deposits and tissue, not intravascular, fibrinolysis (10). 
Importantly, laboratory markers showed complex temporal profiles during the ICU stay, which 
were quite variable among patients (Figure 2 – see also companion paper with individual data). 
For the two functional integrative tests (ETP and GFC), median ranges between daily extreme 
values among patients were 96% and 94 minutes respectively; median ranges for intraindividual 
extreme values over the whole ICU observation period were 49% and 25 minutes, respectively. 
This is a hint for a varying thrombotic risk, and anticoagulation intensity could be tailored in a 
timely manner with frequent reassessments to minimize the bleeding risk.  
This is the first study reporting the daily changes of relevant parameters of hemostasis of severe 










fibrinolysis. It is limited by the small number of patients, but there was a close monitoring of 
each patient (354 patients-days). Day of ICU admission as the baseline for the longitudinal 
follow-up could not represent the same moment in individual disease courses. Moreover, 
effective degree of anticoagulation achieved was variable among patients and over time for a 
given individual. This could have influenced the changes in hemostasis parameters and 
complicates their interpretation, but this is inherent to studies performed in such settings. One 
challenging task is to determine whether increased intensities of anticoagulation actually 
improve relevant hemostasis biomarkers. Regarding endogenous anticoagulants, other 
components than AT should be taken into account as well. Finally, the absence of a control 
group precludes the identification of specificities by comparison to other severe infections.  
In light of these results and of the current knowledge on hemostasis disturbances of COVID-19 
patients, we suggest that a close monitoring of a sensible set hemostatic parameters would be 
useful to assess individual thrombotic risk. We identified an increased thrombin potential and a 
decreased fibrinolytic capacity using newly available tests, which are suitable for clinical use and 
decision making in real time. Further prospective and preferably multicenter studies using 
standard operating protocols for the management of COVID-19 patients are required to validate 
the clinical usefulness of such a monitoring approach.  
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Figure 1: Clinical characteristics of study patients. Horizontal lines with dots represent the 
follow-up period for each patient; those lines end with a vertical line when the patient was 
discharged from the ICU and with a cross when he died (from a suspected massive pulmonary 
embolism (PE), from an ischemic stroke and from bleeding and thrombotic complications in the 
setting of overt disseminated intravascular coagulopathy (DIC)). Blue dots indicate thrombosis 
diagnosis (six deep vein thrombosis (DVT), one PE – or thrombosis within pulmonary arteries, 
one DVT+PE, two ischemic strokes) and red dots represent major bleeding events (i.e. gluteal 
hematoma requiring two embolizations, intracranial bleeding secondary to thrombolysis, 
subacute cerebral hematoma, diffuse multiple bleeding requiring blood transfusions and two 
iatrogenic bleeds – due to an ECMO cannula and to a rectal cannula). Bottom lines represent the 
degree of anticoagulation actually achieved according to anti-Xa plasma levels measured daily 
(IU/mL - heparin anti-Xa activity; STA-Liquid anti-Xa; does not contain dextran): excessive in 
black (i.e. > 0.7 for UFH or > 1.4 for enoxaparin); increased doses in red (i.e. 0.3-0.7 for UFH or 
0.5-1.4 for enoxaparin); prophylactic doses in green (i.e. 0.1-0.3 for UFH or 0.1-0.5 for 
enoxaparin); orange if unknown (LMWH without peak measurement). The implementation of 
GIHP guidance (3) is marked with an asterisk: patients deemed at high thrombotic risk were 
anticoagulated using intermediate doses of heparins (i.e. enoxaparin 1 mg/kg/day; or 
unfractionated heparin (UFH) for an anti-Xa target between 0.3 and 0.5 IU/mL), and patients at 
very high risk were anticoagulated with therapeutic doses (i.e. enoxaparin 1 mg/kg twice daily; 
or UFH for an anti-Xa target between 0.5 and 0.7 IU/mL). The LMWH enoxaparin was 
preferentially used; UFH was administered if renal failure, extracorporeal oxygen membrane 










was present in one patient, represented on the figure by a hash. 
 
Figure 2: Temporal changes of hemostasis parameters since intensive care unit (ICU) admission. 
Medians and interquartile ranges (IQR) are represented till day 30 (few patients had longer ICU 
stay during study period). Grey dots represent individual values and blue lines reference ranges 
(according to the manufacturer’s, determined locally (for prothrombin time and global 
fibrinolytic capacity (GFC)) or according to Calzavarini et al (for ETP) (8)). The population with 
laboratory testing at each day is shown under the individual plots. D0 is the day of admission to 
an ICU, but not necessarily in Namur (there were 11 transfers from a Belgian ICU to Namur ICU 
and one patient already admitted to Namur ICU before the start of the study). Of note there were 
less tests during the first few days (transfers), and less results as well beyond D20 (censoring or 
discharge). Results of GFC are represented with a logarithmic scale. 
CRP, C-reactive protein; FVIII, coagulation factor VIII; ETP, ‘endogenous thrombin potential’ 
(area under the thrombin generation curve); AT, antithrombin; PAI-1, plasminogen activators 
inhibitor 1; GFC, ‘global fibrinolytic capacity’. 
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